A treatment for those with severe alopecia areata, an immune disorder that often results in hair loss, has been approved by the U.S. Food and Drug Administration for the first time.
Alopecia areata, commonly referred to as just alopecia, is an autoimmune disorder in which the body attacks its own hair follicles, causing hair to fall out and often in clumps.
The drug was originally approved in 2018 as a treatment for those suffering from moderately to severely active rheumatoid arthritis and was developed by the pharmaceutical company Eli Lilly. Until now, no FDA-approved treatment for the disease existed.
Olumiant as a treatment for alopecia was studied in two randomized, double-blind, placebo-controlled trials with patients who had at least 50% scalp hair loss for more than six months. The trial participants received either a placebo, 2 milligrams of Olumiant, or 4 milligrams of Olumiant every day for 36 weeks.
In the first trial, 22% of the 184 patients who received 2 milligrams of Olumiant and 35% of the 281 patients who received 4 milligrams of Olumiant achieved "adequate scalp hair coverage," compared to 5% of the 189 patients who received a placebo, the FDA noted.
In the second trial, 17% of the 156 patients who received 2 milligrams of Olumiant and 32% of the 234 patients who received 4 milligrams of Olumiant achieved adequate hair coverage, compared to 3% of the 156 patients who received a placebo.
The results were published this year in the New England Journal of Medicine.
"This is so exciting, because the data clearly show how effective baricitinib is," Dr. Brett King, an associate professor of dermatology at the Yale School of Medicine and on the team who conducted the trials, said in a previous statement.
"These large, controlled trials tell us that we can alleviate some of the suffering from this awful disease," King added.
What is alopecia areata?
Alopecia areata affects more than 300,000 people in the U.S. each year, the FDA said in its statement.
It usually affects the head and face, in which hair typically falls out in small, round patches about the size of a quarter, according to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health. In some cases, hair loss can be more extensive.
Most people with the disease are healthy and have no other symptoms — and the course of the disease can vary from person to person, NIAMS says.
The now-infamous moment at the Oscars when Will Smith marched on stage and smacked Chris Rock over a joke about wife Jada Pinkett Smith’s shaved head inadvertently also shined a light on alopecia areata. Pinkett Smith revealed in 2018 that she was diagnosed with the condition and has often discussed the challenges of hair loss on Instagram and other social media platforms.
Google search data shows searches for the autoimmune condition soared following the Oscars confrontation.
Causes of alopecia areata
For those who have alopecia areata, the body’s immune system mistakenly attacks hair follicles — causing inflammation.
"Researchers do not fully understand what causes the immune attack on hair follicles, but they believe that both genetic and environmental (non-genetic) factors play a role," the NIAMS says.
While anyone can get alopecia areata, some have a greater risk of developing it — including those with a close blood relative with the disease, as well as those who have asthma, hay fever, atopic dermatitis, thyroid disease, vitiligo, or Down syndrome.
The American Academy of Dermatology Association notes on its website how a few cancer patients who received a drug called nivolumab to treat lung cancer and melanoma have also developed alopecia areata, but the link still remains unclear.
"The drug is used to treat lung cancer and melanoma that has spread. Hair loss usually begins a few months after they start treatment. It’s called nivolumab-induced alopecia areata, and the hair loss is considered a good sign," the AAD notes. "This type of hair loss usually means that the drug is working."
FDA approves alopecia drug
Olumiant (baricitinib) is an oral tablet to treat adult patients with severe alopecia areata, the FDA said.
Specifically, the treatment is a Janus kinase (JAK) inhibitor, which blocks the activity of a specific family of enzymes, interfering with the pathway that leads to inflammation, according to the agency.
The FDA said Olumiant is not recommended for use "in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants."
The most common side effects associated with Olumiant included upper respiratory tract infections, headache, acne, high cholesterol, urinary tract infection, liver enzyme elevations, inflammation of hair follicles, fatigue, lower respiratory tract infections, nausea, genital yeast infections, anemia, low number of certain types of white blood cells, abdominal pain, shingles, and weight increase.
"Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia," Dr. Kendall Marcus, director of the Division of Dermatology and Dentistry in the FDA’s Center for Drug Evaluation and Research, said in a statement. "Today’s approval will help fulfill a significant unmet need for patients with severe alopecia areata."
This story was reported from Cincinnati.